IFRX InflaRx N.V. IFRS
Pharmaceutical Preparations · Nasdaq · SEC CIK 1708688 · Reporting currency EUR · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY-82.3%
TTM net income YoY0.9%
TTM EPS YoY12.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin-24,677.9%
Operating margin—
Net margin-155,582.1%
FCF margin—
EBITDA margin—
Returns
ROE-624.6%
ROA-69.5%
ROIC (approx.)—
Asset turnover0.00x
Leverage & solvency
Liabilities / assets24.7%
Debt / equity0.00x
Current ratio4.13x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.77x
Accruals ratio-15.7%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: EUR | FY2025*2025-12-31 | FY2024*2024-12-31 | FY2023*2023-12-31 | FY2022*2022-12-31 | FY2022*2021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | 29,331 | 165,789 | 63,089 | — | — |
| Cost of revenue | 7.27M | 3.32M | 532,262 | — | — |
| Gross profit | -7.24M | -3.15M | -469,173 | — | — |
| R&D expense | 25.72M | 35.36M | 41.02M | 37.53M | 35.70M |
| SG&A expense | 15,963 | 41,400 | 95,205 | 97,413 | 105,790 |
| Operating income | — | — | -44.91M | -32.24M | -47.63M |
| Interest expense | 2,692 | 885 | 16,538 | 23,303 | 10,714 |
| Pretax income | -45.62M | -46.06M | -42.67M | -29.48M | -45.63M |
| Income tax | 12,282 | 5,217 | — | — | 0 |
| Net income | -45.63M | -46.06M | -42.67M | -29.48M | -45.63M |
| EPS (basic) | -0.68 | -0.78 | -0.78 | -0.67 | -1.10 |
| EPS (diluted) | -0.68 | -0.78 | -0.78 | -0.67 | -1.10 |
| Weighted avg. shares (diluted) | — | — | — | — | 41.63M |
| Balance sheet | |||||
| Cash & equivalents | 16.02M | 18.38M | 12.77M | 16.27M | 26.25M |
| Short-term investments | — | — | — | 3,422 | 12.58M |
| Inventory | — | 6.90M | 11.37M | — | — |
| Current assets | 53.63M | 71.66M | 109.47M | 97.41M | 95.68M |
| PP&E, netmay include right-of-use assets (IFRS) | 289,317 | 256,280 | 289,577 | 328,920 | 274,373 |
| Intangibles | — | — | — | 138,905 | 235,216 |
| Total assets | 55.22M | 76.02M | 120.21M | 102.40M | 125.14M |
| Current liabilities | 12.98M | 14.17M | 16.84M | 13.03M | 18.76M |
| Long-term debt | — | — | — | — | 0 |
| Total debt | — | — | — | — | 0 |
| Total liabilities | 13.66M | 14.60M | 17.63M | 14.05M | 19.86M |
| Shareholders' equity | 7.17M | 7.44M | 7.38M | 7.26M | 105.28M |
| Net debt | — | — | — | — | -26.25M |
| Cash flow statement | |||||
| Operating cash flow | -35.31M | -48.56M | -37.81M | -33.74M | -39.94M |
| Investing cash flow | 3.23M | 52.36M | -17.70M | 19.36M | -25.95M |
| Financing cash flow | 33.32M | 386,446 | 52.99M | 1.94M | 61.58M |
| Stock-based compensation | 4.44M | 4.07M | 3.41M | 6.04M | 4.33M |
Free plan shows the latest 5 periods; Pro shows all 11 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· Amounts are in the company's reporting currency, EUR, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.